These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15265903)

  • 1. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis.
    Hollenbaugh JA; Reome J; Dobrzanski M; Dutton RW
    J Immunol; 2004 Aug; 173(3):1738-43. PubMed ID: 15265903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Hylind JC; Dutton RW
    Cancer Res; 2004 Jan; 64(1):406-14. PubMed ID: 14729652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand.
    Liu AN; Mohammed AZ; Rice WR; Fiedeldey DT; Liebermann JS; Whitsett JA; Braciale TJ; Enelow RI
    Am J Respir Cell Mol Biol; 1999 May; 20(5):849-58. PubMed ID: 10226053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
    Helmich BK; Dutton RW
    J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo.
    Prévost-Blondel A; Roth E; Rosenthal FM; Pircher H
    J Immunol; 2000 Apr; 164(7):3645-51. PubMed ID: 10725721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perforin-deficient CD8+ T cells provide immunity to Listeria monocytogenes by a mechanism that is independent of CD95 and IFN-gamma but requires TNF-alpha.
    White DW; Harty JT
    J Immunol; 1998 Jan; 160(2):898-905. PubMed ID: 9551927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
    Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
    J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
    Winter H; Hu HM; Urba WJ; Fox BA
    J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
    Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
    Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
    Caldwell SA; Ryan MH; McDuffie E; Abrams SI
    J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.
    Macgregor JN; Li Q; Chang AE; Braun TM; Hughes DP; McDonagh KT
    Cancer Res; 2006 May; 66(9):4913-21. PubMed ID: 16651448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxicity is mandatory for CD8(+) T cell-mediated contact hypersensitivity.
    Kehren J; Desvignes C; Krasteva M; Ducluzeau MT; Assossou O; Horand F; Hahne M; Kägi D; Kaiserlian D; Nicolas JF
    J Exp Med; 1999 Mar; 189(5):779-86. PubMed ID: 10049941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.
    Komatsu M; Mammolenti M; Jones M; Jurecic R; Sayers TJ; Levy RB
    Blood; 2003 May; 101(10):3991-9. PubMed ID: 12521999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perforin is required for innate and adaptive immunity induced by heat shock protein gp96.
    Strbo N; Oizumi S; Sotosek-Tokmadzic V; Podack ER
    Immunity; 2003 Mar; 18(3):381-90. PubMed ID: 12648455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms.
    Kafrouni MI; Brown GR; Thiele DL
    J Immunol; 2001 Aug; 167(3):1566-74. PubMed ID: 11466378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting edge: antilisterial activity of CD8+ T cells derived from TNF-deficient and TNF/perforin double-deficient mice.
    White DW; Badovinac VP; Kollias G; Harty JT
    J Immunol; 2000 Jul; 165(1):5-9. PubMed ID: 10861027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.